TY  - JOUR
AU  - Becarević, Mirjana
AU  - Nikolić, B.S
AU  - Ignjatović, Svetlana
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3287
AB  - The antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of the IgG and/or IgM isotypes of the antiphospholipid antibodies, thrombosis and/or recurrent pregnancy losses. Various markers of inflammation are associated with clinical and/or laboratory features of APS. Adiponectin (Ad) is a member of the adipocytokines that exert its roles by binding to its receptors (AdR). Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists induced Ad production. The aged Pparg null-mice represented the first animal model that spontaneously develops APS and this model emphasized the importance of PPAR-gamma signaling in the development of APS. Recombinant Ad (rAd) application was beneficial for the improvement of glucose, insulin and lipid levels in mice. Orally active AdR agonist exerted similar effects to Ad in mice. Due to the re-occurrence of thrombotic episodes in APS patients (despite life-long anticoagulation), administration of PPAR-gamma agonists, rAd, or AdR agonists should be further tested in experimental models of APS, which eventually, will provide more data for novel therapeutic strategies that will ameliorate clinical manifestations of the APS.
PB  - Springer Verlag
T2  - Rheumatology International
T1  - Adiponectin: a therapeutic target in the antiphospholipid syndrome?
DO  - 10.1007/s00296-019-04349-x
ER  - 

@article{
author = "Becarević, Mirjana and Nikolić, B.S and Ignjatović, Svetlana",
year = "2019",
abstract = "The antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of the IgG and/or IgM isotypes of the antiphospholipid antibodies, thrombosis and/or recurrent pregnancy losses. Various markers of inflammation are associated with clinical and/or laboratory features of APS. Adiponectin (Ad) is a member of the adipocytokines that exert its roles by binding to its receptors (AdR). Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists induced Ad production. The aged Pparg null-mice represented the first animal model that spontaneously develops APS and this model emphasized the importance of PPAR-gamma signaling in the development of APS. Recombinant Ad (rAd) application was beneficial for the improvement of glucose, insulin and lipid levels in mice. Orally active AdR agonist exerted similar effects to Ad in mice. Due to the re-occurrence of thrombotic episodes in APS patients (despite life-long anticoagulation), administration of PPAR-gamma agonists, rAd, or AdR agonists should be further tested in experimental models of APS, which eventually, will provide more data for novel therapeutic strategies that will ameliorate clinical manifestations of the APS.",
publisher = "Springer Verlag",
journal = "Rheumatology International",
title = "Adiponectin: a therapeutic target in the antiphospholipid syndrome?",
doi = "10.1007/s00296-019-04349-x"
}

Becarević, M., Nikolić, B.S,& Ignjatović, S.. (2019). Adiponectin: a therapeutic target in the antiphospholipid syndrome?. in Rheumatology International
Springer Verlag..
https://doi.org/10.1007/s00296-019-04349-x

Becarević M, Nikolić B, Ignjatović S. Adiponectin: a therapeutic target in the antiphospholipid syndrome?. in Rheumatology International. 2019;.
doi:10.1007/s00296-019-04349-x .

Becarević, Mirjana, Nikolić, B.S, Ignjatović, Svetlana, "Adiponectin: a therapeutic target in the antiphospholipid syndrome?" in Rheumatology International (2019),
https://doi.org/10.1007/s00296-019-04349-x . .